These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11007696)

  • 41. Erythropoietin in patients with ST-segment elevation myocardial infarction.
    Chen Y
    JAMA; 2011 Aug; 306(7):705-6; author reply 706. PubMed ID: 21846847
    [No Abstract]   [Full Text] [Related]  

  • 42. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin-converting enzyme inhibitors.
    Ertürk S; Ateş K; Duman N; Karatan O; Erbay B; Ertuğ E
    Nephrol Dial Transplant; 1996 Feb; 11(2):396-7. PubMed ID: 8700371
    [No Abstract]   [Full Text] [Related]  

  • 45. Case history. 2: The use of epoetin alfa before high-dose chemotherapy.
    Mertelsmann R
    Ann Oncol; 1997; 8 Suppl 3():S13. PubMed ID: 9341961
    [No Abstract]   [Full Text] [Related]  

  • 46. Questionable conclusions about epoetin alfa.
    Kruse MW; Lee JJ
    Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
    [No Abstract]   [Full Text] [Related]  

  • 47. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
    Hess E; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881
    [No Abstract]   [Full Text] [Related]  

  • 50. Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?
    Yeh PY; Liao FL; Lin SL
    J Formos Med Assoc; 2013 Nov; 112(11):655-6. PubMed ID: 23598245
    [No Abstract]   [Full Text] [Related]  

  • 51. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S; Plavljanić E; Trkulja V
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
    Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S
    J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177
    [No Abstract]   [Full Text] [Related]  

  • 55. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
    Nakagawa T
    Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
    [No Abstract]   [Full Text] [Related]  

  • 56. Erythropoiesis stimulating agents: a personal journey.
    Leyland-Jones B
    J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
    [No Abstract]   [Full Text] [Related]  

  • 57. Proceedings of the roundtable of experts in surgery blood management. Vienna, Austria, April 7-9, 1995.
    Semin Hematol; 1996 Apr; 33(2 Suppl 2):1-80. PubMed ID: 8999552
    [No Abstract]   [Full Text] [Related]  

  • 58. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
    Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
    Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
    Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.